Bart Rijnders

Professor

Erasmus University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Bart Rijnders is a faculty member at Erasmus MC, University Medical Center in the Netherlands. His research focuses on hematological diseases, infectious diseases, and the impact of viral infections on individuals living with HIV. Recent publications include studies on the therapeutic value of chest X-rays in hematological patients, COVID-19 vaccine immunogenicity, and the diagnosis of pulmonary aspergillosis. He actively contributes to understanding trends in HIV-related health outcomes and the effectiveness of antiretroviral therapies.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Anna H.E. Roukens

Leiden University Medical Center

NETHERLANDS

View details

Adam Anas

Erasmus University Rotterdam

NETHERLANDS

View details

Isabel Spriet

BELGIUM

View details

Wendy Oldenmenger

Erasmus University Rotterdam

NETHERLANDS

View details

Lars Østergaard

Aarhus University

DENMARK

View details

Casper Rokx

Erasmus University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bart Rijnders

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Limited Diagnostic and Therapeutic Value of Chest X-Rays in Hematological Patients With Febrile Neutropenia

Longitudinal trajectories of sexual behavior and incident hepatitis C reinfection among men who have sex with men with HIV

Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4 T-cell count in the Netherlands

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19

Low coverage of hepatitis D virus testing in individuals with hepatitis B virus and HIV, the Netherlands, 2000 to 2022

Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease

Trends in Mortality in People With HIV From 1999 through 2020

Superiority Trials in Invasive Aspergillosis

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients

Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients

Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study

Invasive Pulmonary Aspergillosis Goes Viral Again?

The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement.

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.

Frequency of Positive Aspergillus Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the ICU.

HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.

Nieuw onderzoek naar plasma-antistofbehandeling voor niet-opgenomen COVID-19-patiënten.

Point of care aspergillus testing in intensive care patients.

Collaborators (6)

Anna H.E. Roukens

Adam Anas

Isabel Spriet

Wendy Oldenmenger

Lars Østergaard

Casper Rokx

Make your next move.